Mahmoud Al-Kofahi

Mahmoud Al-Kofahi

Auto-generated profile, based on publicly available information

Mahmoud Al-Kofahi

Department of Experimental and Clinical Pharmacology, College of Pharmacy University of Minnesota Minneapolis Minnesota USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
MAMahmoud Al-Kofahi
Mahmoud Al-Kofahi
Seiichi OmuraSeiichi Omura
Seiichi Omura
ITIkuo Tsunoda
Ikuo Tsunoda
Fumitaka SatoFumitaka Sato
Fumitaka Sato
FBFelix Becker
Felix Becker
Jonathan Steven AlexanderJonathan Steven Alexander
Jonathan Steven Alexander

27 April 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ASAbdelrahman Saqr
Abdelrahman Saqr
BCBrooke Carlson
Brooke Carlson
Christopher StaleyChristopher Staley
Christopher Staley
ARArmin Rashidi
Armin Rashidi
MAMahmoud Al-Kofahi
Mahmoud Al-Kofahi
PJPamala A. Jacobson
Pamala A. Jacobson
Mycophenolate mofetil (MMF) is an important immunosuppressant used after allogeneic hematopoietic cell transplantation (HCT). MMF has a narrow therapeutic index, and blood concentrations of mycophenolic acid (MPA), the active component of MMF, are highly variable. Low MPA concentrations are associated with the risk of graft-versus-host disease (GVHD), whereas high concentrations are associated with toxicity. Reasons for variability are not well known and may include the presence of β-glucuronidase-producing bacteria in the gastrointestinal tract, which enhance MPA enterohepatic recirculation (EHR) by transforming MPA metabolites formed in the liver back to MPA. This study was conducted to determine whether individuals with high MPA EHR have a greater abundance of β-glucuronidase-producing bacteria in their stool and higher MPA concentrations compared with those with low EHR. We conducted a pharmacomicrobiomics study in 20 adult HCT recipients receiving a myeloablative or reduced-intensity preparative regimen. Participants received MMF 1 g i.v. every 8 hours with tacrolimus. Intensive pharmacokinetic sampling of MMF was conducted before hospital discharge; total MPA, MPA glucuronide (MPAG), and acyl-glucuronide metabolite (acylMPAG) were measured. EHR was defined as the ratio of MPA area under the concentration-versus-time curve (AUC)4-8 to MPA AUC0-8. Differences in stool microbiome diversity and composition, determined by shotgun metagenomic sequencing, were compared above and below the median EHR (22%; range, 5% to 44%). The median EHR was 12% in the low EHR group and 29% in the high EHR group. MPA troughs, MPA AUC4-8, and acyl-glucuronide metabolite (acylMPAG) AUC4-8/AUC0-8 ratio were greater in the high EHR group compared with the low EHR group (1.53 μg/mL versus .28 μg/mL [P = .0001], 7.33 hour·μg/mL versus 1.79 hour·μg/mL [P = .0003], and .33 hour·μg/mL versus .24 hour·μg/mL [P = .0007], respectively). MPA AUC0-8 was greater in the high EHR group than in the low EHR group, and the difference trended toward significance (22.8 hour·μg/mL versus 15.3 hour·μg/mL; P = .06). Bacteroides vulgatus, Bacteroides stercoris, and Bacteroides thetaiotaomicron were 1.2- to 2.4-fold more abundant (P = .039, .024, and .046, respectively) in the high EHR group. MPA EHR was positively correlated with B. vulgatus (⍴ = .58; P ≤ .01) and B. thetaiotaomicron (⍴ = .46; P < .05) and negatively correlated with Blautia hydrogenotrophica (⍴ = -.53; P < .05). Therapeutic MPA troughs were achieved in 80% of patients in the high EHR group but in no patients in the low EHR group. There was a trend toward differences in MPA AUC0-8 and MPA concentration at steady-state (μg/mL) between the high EHR group versus the low EHR group (P = .06). MPA EHR was variable. Patients with high MPA EHR had greater abundance of Bacteroides species in stool and higher MPA exposure compared with patients with low MPA EHR. Therefore, Bacteroides may be protective against poor outcomes, such as graft-versus-host disease, in some patients but may increase the risk of MPA adverse effects in others. These data need to be confirmed and studied after oral MMF therapy.

18 May 2015 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MAM Al‐Kofahi
M Al‐Kofahi
FBFelix Becker
Felix Becker
Felicity N. E. GavinsFelicity N. E. Gavins
Felicity N. E. Gavins
MWMatthew Woolard
Matthew Woolard
ITIkuo Tsunoda
Ikuo Tsunoda
Jonathan Steven AlexanderJonathan Steven Alexander
Jonathan Steven Alexander
Background and Purpose: The lymphatic system maintains tissue homeostasis by unidirectional lymph flow, maintained by tonic and phasic contractions within subunits, ‘lymphangions’. Here we have studied the effects of the inflammatory cytokineIL‐1β on tonic contraction of rat mesenteric lymphatic muscle cells (RMLMC).Experimental Approach: We measuredIL‐1β in colon‐conditioned media (CM) from acute (AC‐CM, dextran sodium sulfate) and chronic (CC‐CM, T‐cell transfer) colitis‐induced mice and corresponding controls (Con‐AC/CC‐CM). We examined tonic contractility ofRMLMCin response toCM, the cytokines h‐IL‐1β or h‐TNF‐α (5, 10, 20 ng·mL−1), with or withoutCOXinhibitors [TFAP(10−5 M), diclofenac (0.2 × 10−5 M)],PGE2(10−5 M)],IL‐1‐receptor antagonist,Anakinra (5 μg·mL−1), or a selective prostanoidEP4receptor antagonist,GW627368X(10−6and 10−7 M).Key Results: Tonic contractility ofRMLMCwas reduced byAC‐ andCC‐CMcompared with corresponding control culture media,Con‐AC/CC‐CM.IL‐1β orTNF‐α was not found in Con‐AC/CC‐CM, but detected inAC‐ andCC‐CM. h‐IL‐1β concentration‐dependently decreasedRMLMCcontractility, whereas h‐TNF‐α showed no effect. Anakinra blocked h‐IL‐1β‐inducedRMLMCrelaxation, and withAC‐CM,restored contractility to RMLMC.IL‐1β increasedCOX‐2 protein andPGE2production inRMLMC..PGE2induced relaxations inRMLMC, comparable to h‐IL‐1β. Conversely,COX‐2 andEP4receptor inhibition reversed relaxation induced byIL‐1β.Conclusions and Implications: TheIL‐1β‐induced decrease inRMLMCtonic contraction wasCOX‐2 dependent, and mediated byPGE2. In experimental colitis,IL‐1β and tonic lymphatic contractility were causally related, as this cytokine was critical for the relaxation induced byAC‐CMand pharmacological blockade ofIL‐1β restored tonic contraction.

20 July 2017 in Clinical and Experimental Neuroimmunology
Verified
Journal Article
Closed access
PDF file
MAMahmoud Al‐Kofahi
Mahmoud Al‐Kofahi
JYJ. Winny Yun
J. Winny Yun
AMAlireza Minagar
Alireza Minagar
Jonathan Steven AlexanderJonathan Steven Alexander
Jonathan Steven Alexander

26 July 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MAMahmoud Al‐Kofahi
Mahmoud Al‐Kofahi
MAMariam A. Ahmed
Mariam A. Ahmed
MJMutaz Jaber
Mutaz Jaber
TTThang N. Tran
Thang N. Tran
BWBrian A. Willis
Brian A. Willis
KSKyriakie Sarafoglou
Kyriakie Sarafoglou
Aims: The aim of this study was to characterize the pharmacokinetic/pharmacodynamic relationships of cortisol and the adrenal biomarkers 17‐hydroxyprogesterone and androstenedione in children with congenital adrenal hyperplasia (CAH).Methods: A nonlinear mixed‐effect modelling approach was used to analyse cortisol, 17‐hydroxyprogesterone and androstenedione concentrations obtained over 6 hours from children with CAH (n = 50). A circadian rhythm was evident and the model leveraged literature information on circadian rhythm in untreated children with CAH. Indirect response models were applied in which cortisol inhibited the production rate of all three compounds using an Imax model.Results: Cortisol was characterized by a one‐compartment model with apparent clearance and volume of distribution estimated at 22.9 L/h/70 kg and 41.1 L/70 kg, respectively. The IC50 values of cortisol concentrations for cortisol, 17‐hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively. The inhibitory effect was found to be more potent on 17OHP than D4A, and the IC50 values were higher in salt‐wasting subjects than simple virilizers. Production rates of cortisol, 17‐hydroxyprogesterone and androstenedione were higher in simple‐virilizer subjects. Half‐lives of cortisol, 17‐hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.Conclusion: Rapidly changing biomarker responses to cortisol concentrations highlight that single measurements provide volatile information about a child's disease control. Our model closely captured observed cortisol, 17‐hydroxyprogesterone and androstenedione concentrations. It can be used to predict concentrations over 24 hours and allows many novel exposure metrics to be calculated, e.g., AUC, AUC‐above‐threshold, time‐within‐range, etc. Our long‐range goal is to uncover dose–exposure–outcome relationships that clinicians can use in adjusting hydrocortisone dose and timing.

24 August 2023 in Blood
Verified
Journal Article
Closed access
PDF file
TTTakuto Takahashi
Takuto Takahashi
MAMahmoud Al-Kofahi
Mahmoud Al-Kofahi
MJMutaz Jaber
Mutaz Jaber
BBBrandi Bratrude
Brandi Bratrude
KBKayla M Betz
Kayla M Betz
LKLeslie S. Kean
Leslie S. Kean
In the ABA2 study, the T-cell costimulation blockade agent, abatacept, was safe and effective in preventing acute graft-versus-host disease (aGVHD) after unrelated-donor hematopoietic cell transplant (HCT), leading to US Food and Drug Administration approval. Here, we performed a determination of abatacept pharmacokinetics (PK), which enabled an examination of how abatacept exposure-response relationships affected clinical outcomes. We performed a population PK analysis of IV abatacept using nonlinear mixed-effect modeling and assessed the association between abatacept exposure and key transplant outcomes. We tested the association between the trough after dose 1 (Ctrough_1) and grade (GR) 2 or 4 aGVHD (GR2-4 aGVHD) through day +100. An optimal Ctrough_1 threshold was identified via recursive partitioning and classification tree analysis. This demonstrated that abatacept PK was characterized by a 2-compartment model with first-order elimination. The ABA2 dosing regimen was based on previous work targeting a steady-state abatacept trough of 10 μg/mL. However, a higher Ctrough_1 (≥39 μg/mL, attained in ∼60% of patients on ABA2) was associated with a favorable GR2-4 aGVHD risk (hazard ratio, 0.35; 95% confidence interval, 0.19-0.65; P < .001), with a Ctrough_1 <39 μg/mL associated with GR2-4 aGVHD risk indistinguishable from placebo (P = .37). Importantly, no significant association was found between Ctrough_1 and key safety indicators, including relapse, and cytomegalovirus or Epstein-Barr virus viremia. These data demonstrate that a higher abatacept Ctrough_1 (≥39 μg/mL) was associated with a favorable GR2-4 aGVHD risk, without any observed exposure-toxicity relationships. This trial was registered at www.clinicaltrials.gov as #NCT01743131.